Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
The Food and Drug Administration is expected to approve the first new type of drug for schizophrenia in decades. Called KarXT, the medicine appears to be effective, but its main advantage over current ...
Pete McCown has experienced Oaklawn’s services directly due to his son’s four-year struggle with schizophrenia. McCown, president of the Community Foundation of Elkhart County, spoke Wednesday as ...
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.
British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of ...
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma ...
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...